Interaction between Helicobacter pylori, diet, and genetic polymorphisms as related to non-cancer diseases

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 667, Issue 1-2, 2009, Pages 142-157

  Izzotti, Alberto ^a   Durando, Paolo ^a   Ansaldi, Filippo ^a   Gianiorio, Fabio ^b   Pulliero, Alessandra ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Environmental risk factors; Genetic polymorphisms; Helicobacter pylori; Host bacterium interaction; Non cancer diseases; Oxidative DNA damage

Indexed keywords

ANTIOXIDANT;

ATHEROSCLEROSIS; BACTERIAL GENETICS; CARDIOVASCULAR DISEASE; DEGENERATIVE DISEASE; DIET; DISEASE ASSOCIATION; DNA DAMAGE; DNA POLYMORPHISM; DUODENUM ULCER; ENVIRONMENTAL EXPOSURE; EYE DISEASE; GASTRITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; GENETIC POLYMORPHISM; GENOTOXICITY; GENOTYPE; GRAM NEGATIVE BACTERIUM; HEALTH STATUS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HOST; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFLAMMATION; ISCHEMIC HEART DISEASE; MUTAGENESIS; NONCANCER DISEASE; PHYSICAL DISEASE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SKIN DISEASE; STOMACH CANCER; STOMACH ULCER;

DIET; DNA DAMAGE; ENVIRONMENTAL POLLUTANTS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INFLAMMATION; LIFE STYLE; OXIDATIVE STRESS; POLYMORPHISM, GENETIC;

BACTERIA (MICROORGANISMS); HELICOBACTER PYLORI; NEGIBACTERIA;

EID: 67649285714     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2009.02.002     Document Type: Review

References (152)

1. Malaty H.M. Epidemiology of Helicobacter pylori infection. Best Pract. Res. Clin. Gastroenterol. 21 (2007) 205-214
2. Crowe S.E. Helicobacter infection, chronic inflammation, and the development of malignancy. Curr. Opin. Gastroenterol. 21 (2005) 32-38
3. Wilson K.T., and Crabtree J.E. Immunology of Helicobacter pylori: insights into the failure of the immune response and perspectives on vaccine studies. Gastroenterology 133 (2007) 288-308
4. Konturek S.J., Konturek P.C., Konturek J.W., Plonka M., Czesnikiewicz-Guzik M., Brzozowski T., and Bielanski W. Helicobacter pylori and its involvement in gastritis and peptic ulcer formation. J. Physiol. Pharmacol. 57 (2006) 29-50
5. Kandulski, Selgrad M., and Malfertheiner P. Helicobacter pylori infection: a clinical overview. Dig. Liver Dis. 40 (2008) 619-626
6. Kobayashi H., Kamiya S., Suzuki T., Kohda K., Muramatsu S., Kurumada T., Ohta U., Miyazawa M., Kimura N., Mutoh N., Shirai T., Takagi A., Harasawa S., Tani N., and Miwa T. The effect of Helicobacter pylori on gastric acid secretion by isolated parietal cells from a guinea pig-association with production of vacuolating toxin by H. pylori. Scand. J. Gastroenterol. 31 (1996) 428-433
7. Konturek P., Brzozowski T., Karczewska E., Duda A., Bielański W., Hahn E.G., and Konturek S.J. Water extracts of Helicobacter pylori suppress the expression of histidine decarboxylase and reduce histamine content in the rat gastric mucosa. Digestion 62 (2000) 100-109
8. Nedrud J.G., Blanchard S.S., and Czinn S.J. Helicobacter pylori inflammation and immunity. Helicobacter 7 (2002) 24-29
9. Csendes A., Braghetto I., and Smok G. Type IV gastric ulcer: a new hypothesis. Surgery 101 (1987) 361-366
10. Dixon M.F. Prospects for intervention in gastric carcinogenesis: reversibility of gastric atrophy and intestinal metaplasia. Gut 49 (2001) 2-4
11. Schlemper R.J., van der Werf S.D., Biemond I., and Lamers C.B. Seroepidemiology of gastritis in Japanese and Dutch male employees with and without ulcer disease. Eur. J. Gastroenterol. Hepatol. 88 (1996) 33-39
12. Raghunath A., Hugin A.P.S., Wooff D., and Childs S. Prevalence of Helicobacter in patients with gastro-oesophageal reflux disease: systematic review. Br. Med. J. 326 (2003) 737
13. Andreassi M.G. Metabolic syndrome, diabetes and atherosclerosis: influence of gene-environment interaction. Mutat. Res. November (2008)
14. Ross R. Atherosclerosis: an inflammatory disease. N. Engl. J. Med. 340 (1999) 115-126
15. Sawayama Y., Tatsukawa M., Okada K., Maeda N., Shimizu C., Kikuchi K., and Hayashi J. Association of Chlamydia pneumoniae antibody with the cholesterol-lowering effect of statins. Atherosclerosis 171 (2003) 281-285
16. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362 (1993) 801-809
17. Stone A.F., and Mendall M.A. Helicobacter pylori is an aetiological factor for ischaemic heart disease: the case in favour. Dig. Liver Dis. 32 (2000) 62-64
18. Franceschi F., Sepulveda A.R., Gasbarrini A., Pola P., Silveri N.G., Gasbarrini G., Graham D.Y., and Genta R.M. Cross-reactivity of anti-CagA antibodies with vascular wall antigens: possible pathogenic link between Helicobacter pylori infection and atherosclerosis. Circulation 106 (2002) 430-434
19. Lenzi C., Palazzuoli A., Giordano N., Alegente G., Gonnelli C., Campagna M.S., Santucci A., Sozzi M., Papakostas P., Rollo F., Nuti R., and Figura N. H. pylori infection and systemic antibodies to CagA and heat shock protein 60 in patients with coronary heart disease. World J. Gastroenterol. 12 (2006) 7815-7820
20. Jha H.C., Prasad J., and Mittal A. High immunoglobulin A seropositivity for combined Chlamydia pneumoniae, Helicobacter pylori infection, and high-sensitivity C-reactive protein in coronary artery disease patients in India can serve as atherosclerotic marker. Heart Vessels 23 (2008) 390-396
21. Sawayama Y., Ariyama I., Hamada M., Otaguro S., Machi T., Taira Y., and Hayashi J. Association between chronic Helicobacter pylori infection and acute ischemic stroke: Fukuoka Harasanshin Atherosclerosis Trial (FHAT). Atherosclerosis 178 (2005) 303-309
22. Kawahara Y., Yokota K., Mizuno M., Yunoki N., Uesu T., Okada H., Kobayashi K., Hirai Y., Oguma K., and Tsuji T. Antibodies to human gastric epithelial cells and heat shock protein 60 in Helicobacter pylori positive mucosa associated lymphoid tissue lymphoma. Gut 45 (1999) 20-23
23. Benagiano M., Azzurri A., Ciervo A., Amedei A., Tamburini C., Ferrari M., Telford J.L., Baldari C.T., Romagnani S., Cassone A., D'Elios M.M., and Del Prete G. T helper type 1 lymphocytes drive inflammation in human atherosclerotic lesions. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 6658-6663
24. Izzotti A., Cartiglia C., Lewtas J., and De Flora S. Increased DNA alterations in atherosclerotic lesions of individuals lacking the GSTM1 genotype. FASEB J. 15 (2001) 752-757
25. Danesh J., Collins R., and Peto R. Chronic infections and coronary heart disease: is there a link?. Lancet 350 (1997) 430-436
26. Lichtman A.H., Clinton S.K., Iiyama K., Connelly P.W., Libby P., and Cybulsky M.I. Hyperlipidemia and atherosclerotic lesion development in LDL receptor-deficient mice fed defined semipurified diets with and without cholate. Arterioscler. Thromb. Vasc. Biol. 19 (1999) 1938-1944
27. Kanbay M., Gür G., Yücel M., Yilmaz U., and Boyacioǧlu S. Does eradication of Helicobacter pylori infection help normalize serum lipid and CRP levels?. Dig. Dis. Sci. 50 (2005) 1228-1231
28. Ozer B., Serin E., Gumurdulu Y., Kayaselcuk F., Anarat R., Gur G., Kul K., Guclu M., and Boyacioglu S. Helicobacter pylori eradication lowers serum homocysteine level in patients without gastric atrophy. World J. Gastroenterol. 11 (2005) 2764-2767
29. Izzotti A., Piana G., Vercelli M., Perrone L., and De Flora S. Survival of atherosclerotic patients as related to oxidative stress and gene polymorphisms. Mutat. Res. Rev. Mutat. Res.-Fundam. Mol. Mech. Mutagen. 128 621 (2007) 119
30. Gillum R.F. Infection with Helicobacter pylori, coronary heart disease, cardiovascular risk factors, and systemic inflammation: the Third National Health and Nutrition Examination. Survey J. Natl. Med. Assoc. 96 (2004) 1470-1476
31. Lee W.Y., Yoon W.T., Shin H.Y., Jeon S.H., and Rhee P.L. Helicobacter pylori infection and motor fluctuations in patients with Parkinson's disease. H. pylori Mov. Disord. 23 (2008) 1696-1700
32. Lang A.E., and Lozano A.M. Parkinson's disease. First of two part. New. Engl. J. Med. 339 (1998) 1044-1053
33. Migliore L., and Coppedè F. Environmental-induced oxidative stress in neurodegenerative disorders and aging. Mutat. Res. October (2008)
34. Dobbs S.M., Dobbs R.J., Weller C., and Charlett A. Link between Helicobacter pylori infection and idiopathic parkinsonism. Med. Hypotheses 55 (2000) 93-98
35. Przuntek H., Müller T.H., and Riederer P. Diagnostic staging of Parkinson's disease: conceptual aspects. J. Neural. Transm. 111 (2004) 201-216
36. Attallah A.M., Toson E.A., Ibrahim G.G., and Bakr. Detection of a Helicobacter pylori antigen in cerebrospinal fluid of patients with meningitis. Immunoassay Immunochem. 28 (2007) 25-33
37. Charlett A., Dobbs R.J., Weller C., Dobbs S.M., and Peterson D.W. Evidence for autoimmunity triggered by Helicobacter pylori in idiopathic parkinsonism. Br. J. Clin. Pharmacol. 49 (2000) 506
38. Lundgren A., Suri-Payer E., Enarsson K., Svennerholm A.M., and Lundin B.S. Helicobacter pylori-specific CD4+CD25 high regulatory T cells suppress memory T cell responses to H. pylori in infected individuals. Infect. Immun. 71 (2003) 1755-1762
39. Kountouras J., Gavalas E., Zavos C., Stergiopoulos C., Chatzopoulos D., Kapetanakis N., and Gisakis D. Alzheimer's disease and Helicobacter pylori infection: defective immune regulation and apoptosis as proposed common links. Med. Hypotheses 68 (2007) 378-388
40. Saccà S.C., Bolognesi C., Battistella A., Bagnis A., and Izzotti A. Gene-environment interactions in ocular diseases. Mutat. Res. November (2008)
41. Fu S., Ramanujam K.S., Wong A., Fantry G.T., Drachenberg C.B., James S.P., Meltzer S.J., and Wilson K.T. Increased expression and cellular localization of inducible nitric oxide synthase and cyclooxygenase 2 in Helicobacter pylori gastritis. Gastroenterology 116 (1999) 1319-1329
42. Kountouras J., Mylopoulos N., Boura P., Bessas C., Chatzopoulos D., Venizelos J., and Zavos C. Relationship between Helicobacter pylori infection and glaucoma. Ophthalmology 108 (2001) 599-604
43. Kountouras J., Zavos C., Grigoriadis N., Deretzi G., Katsinelos P., and Tzilves D. Helicobacter pylori infection as a risk factor for primary open-angle glaucoma. Clin. Exp. Ophthalmol. 36 (2008) 196
44. Tezel G., Kass M.A., Kolker A.E., Becker B., and Wax M.B. Plasma and aqueous humor endothelium levels in primary open-angle glaucoma. Glaucoma (1997) 683-689
45. Saccà S.C., Pascotto A., Venturino G.M., Prigione G., Mastromarino A., Baldi F., Bilardi C., Savarino V., Brusati C., and Rebora A. Prevalence and treatment of Helicobacter pylori in patients with blepharitis. Invest. Ophtalmol. Vis. Sci. 47 (2006) 501-508
46. McCulley J.P., and Shine W.E. Eyelid disorders: the meibomian gland, blepharitis, and contact lenses. Eye Contact Lens 29 (2003) S93-S95
47. Baz K., Cimen B., Kokturk A., Aslan G., Ikizoglu G., Demirseren D., Kanik A., and Atik U. Plasma reactive oxygen species activity and antioxidant potential levels in rosacea patients: correlation with seropositivity to Helicobacter pylori. Int. J. Dermatol. 43 (2004) 494-497
48. Ghanem V.C., Mehra N., Wong S., and Mannis M.J. The prevalence of ocular signs in acne rosacea: comparing patients from ophthalmology and dermatology clinics. Cornea 22 (2003) 230-233
49. Daković Z., Vesić S., Vuković J., Milenković S., Janković-Terzić K., and Dukić S. Ocular rosacea and treatment of symptomatic Helicobacter pylori infection: a case series. Acta Dermatovenerol. Alp Panonica Adriat 16 (2007) 83-86
50. Kendall S.N. Remission of rosacea induced by reduction of gut transit time. Clin. Exp. Dermatol. 29 (2004) 297-299
51. Vitali C., and Bombardieri S. Sjögren's syndrome, mixed cryoglobulinemia and the monoclonal gammopathies. Clin. Exp. Rheum. 14 (1996) S59-S64
52. Theander E., Nilsson I., Manthorpe R., Jacobsson L.T., and Wadstrom T. Seroprevalence of Helicobacter pylori in primary Sjogren's syndrome. Clin. Exp. Rheumatol. 19 (2001) 633-638
53. Horiuchi M., Yamano S., Inoue H., Ishii J., Nagata Y., Adachi H., Ono M., Renard J.N., Mizuno F., Hayashi Y., and Saito I. Possible involvement of IL-12 expression by Epstein-Barr virus in Sjögren syndrome. J. Clin. Pathol. 52 (1999) 833-837
54. Locke III G.R. Prevalence, incidence and natural history of dyspepsia and functional dyspepsia. Baillieres Clin. Gastroenterol. 12 (1998) 435-442
55. Akamatsu H., and Horio T. The possible role of reactive oxygen species generated by neutrophils in mediating acne inflammation. Dermatology 196 (1998) 82-85
56. Everett S.M., Drake I.M., White K.L.M., et al. Antioxidant vitamin supplements do not reduce reactive oxygen species activity in Helicobacter pylori gastritis in the short term. Br. J. Nutr. 87 (2002) 3-11
57. Woodward M., Tunstall-Pedoe H., and McColl K. Helicobacter pylori infection reduces systemic availability of dietary vitamin C. Eur. J. Gastroenterol. Hepatol. 13 (2001) 233-237
58. Qayoom S., and Ahmad Q.M. Psoriasis and Helicobacter pylori. Ind. J. Dermatol. Venereol. Leprol. 69 (2003) 133-134
59. Son S.W., Kim I.H., Oh C.H., and Kim J.G. The response of rosacea to eradication of Helicobacter pylori. Br. J. Dermatol. 140 (1999) 984-985
60. Szlachcic A. The link between Helicobacter pylori infection and rosacea. J. Eur. Acad. Dermatol. Venereol. 16 (2002) 328-333
61. Plewig G., and Jansen T. Rosacea. In: Freedberg I.M., Eisen A.Z., and Wolff K. (Eds). Dermatology in General Medicine. fifth edn. (1999), McGraw-Hill, Philadelphia 785-794
62. Gurer M.A., Erel A., Erbas D., Caǧlar K., and Atahan C. The seroprevalence of Helicobacter pylori and nitric oxide in acne rosacea. Int. J. Dermatol. 41 (2002) 768-770
63. Alem M., Alem N., Cohen H., England T., Hamedi N., Moussazadeh M., Roth J.A., and Shen G.Q. Diagnostic value of detection of IgM antibodies to Helicobacter pylori. Exp. Mol. Pathol. 72 (2002) 77-83
64. Hohmann A.W., Booth K., Peters V., Gordon D.L., and Comacchio R.M. Common epitope on HIV p24 and human platelets. Lancet 342 (1993) 1274-1275
65. Soldinger E., Pilia M.C., Piubello W., and Nadali G. Multi-resistant idiopathic thrombocytopenia successfully treated by eradication of Helicobacter pylori. Dig. Liver Dis. 33 (2000) 732
66. Franceschi F., Christodoulides N., Kroll M.H., Emilia G., Luppi M., and Torelli G. Helicobacter pylori and idiopathic thrombocytopenic purpura. Ann. Intern. Med. 140 (2004) 766-767
67. Takahashi T., Yujiri T., Shinohara K., Inoue Y., Sato Y., Fujii Y., Okubo M., and Zaitsu Y. Molecular mimicry by Helicobacter pylori CagA protein may be involved in the pathogenesis of H. pylori-associated chronic idiopathic thrombocytopenic purpura. Br. J. Haematol. 124 (2004) 91-96
68. Erel A., Öztaş M., and İlter N. Helicobacter pylori seroprevalence in patients with acne rosacea. J. Eur. Acad. Dermatol. Venereol. 5 (1995) 151
69. Shapiro K.B., and Hotchkiss J.H. Induction of nitric oxide synthesis in murine macrophages by Helicobacter pylori. Cancer Lett. 102 (1996) 49-56
70. Liu R.L., and Hotchkiss J.H. Potential genotoxicity of chronically elevated nitric oxide: a review. Mutat. Res. 339 (1995) 73-89
71. Ziebarth D., Spiegelhalder B., and Bartsch H. N-Nitrosation of medicinal drugs catalysed by bacteria from human saliva and gastrointestinal tract, including Helicobacter pylori. Carcinogenesis 18 (1997) 383-389
72. Mowat C., Carswell A., Wirz A., and McColl K.E.L. Omeprazole and dietary nitrate independently affect levels of Vitamin C and nitrite in gastric juice. Gastroenterology 116 (1999) 813-822
73. De Flora S., Izzotti A., Randerath K., Randerath E., Bartsch H., Nair J., Balansky R., Van Schooten F., Degan P., Fronza G., Walsh D., and e Lewtas J. DNA adducts and chronic degenerative diseases. pathogenetic relevance and implications in preventive medicine. Mutat. Res. 366 (1996) 197-238
74. Tsugane S., and Sasazuki S. Diet and the risk of gastric cancer: review of epidemiological evidence. Gastric Cancer 10 (2007) 75-83
75. Bartsch H., Ohshima H., and Pignatelli B. Inhibitors of endogenous nitrosation: mechanisms and implications in human cancer prevention. Mutat. Res. 202 (1988) 307-324
76. Takahashi M., and Hasegawa R. Enhancing effects of dietary salt on both initiation and promotion stages of rat gastric carcinogenesis. Princess Takamatsu Symp. 16 (1985) 169-182
77. Fox J.G., Dangler C.A., Taylor N.S., King A., Koh T.J., and Wang T.C. High-salt diet induces gastric epithelial hyperplasia and parietal cell loss, and enhances Helicobacter pylori colonization in C57BL/6 mice. Cancer Res. 59 (1999) 4823-4828
78. Lee S.A., Kang D., Shim K.N., Choe J.W., Hong W.S., and Choi H. Effect of diet and Helicobacter pylori infection to the risk of early gastric cancer. J. Epidemiol. 13 (2003) 162-168
79. Block G., Patterson B., and Subar A. Fruit, vegetables, and cancer prevention: a review of the epidemiological evidence. Nutr. Cancer 18 (1992) 1-29
80. Bergin I.L., Sheppard B.J., and Fox J.C. Helicobacter pylori infection and high dietary salt independently induce atrophic gastritis and intestinal metaplasia in commercially available outbreed Mongolian gerbils. Dig. Dis. Sci. 48 (2003) 475-485
81. Byrd-Bredbenner C., Lagiou P., and Trichopoulou A. A comparison of household food availability in 11 countries. J. Hum. Nutr. Dietet. 13 (2000) 197
82. Knoops K.T., de Groot L.C., Kromhout D., Perrin A.E., Moreiras-Varela O., Menotti A., and van Staveren W.A. Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and women: the HALE project. JAMA 292 (2004) 1433-1439
83. Riboli N., Slimani R., and Kaaks R. Identifiability of food components for cancer chemoprevention. IARC Sci. Publ. 139 (1996) 23-31
84. Mackerness C.W., Leach S.A., Thompson M.H., and Hill M.J. The inhibition of bacterially mediated N-nitrosation by vitamin C: relevance to inhibition of endogenous N-nitrosation in the achlorhydric stomach. Carcinogenesis 10 (1989) 397-399
85. O'Connor H.J., Schorah C.J., Habibzedah N., Axon A.T.R., and Cockel R. Vitamin C in the human stomach: relation to gastric pH, gastroduodenal disease, and possible sources. Gut 30 (1989) 436-442
86. Sugimoto N., Yoshida N., Nakamura Y., Ichikawa H., and Naito Y. Influence of vitamin E on gastric mucosal injury induced by Helicobacter pylori infection. Pol. Biofactors 28 (2006) 9-19
87. Safranow K., Korzonek M., Szmatłoch E., Rzeuski R., Sulzyc-Bielicka T., Okanoue V., and Yoshikawa. Vitamin C and uric acid concentrations in plasma and gastric mucosa in patients regularly consuming vegetables, fruits and fruit juices. T. Arch. Med. Wewn. 105 (2001) 383-389
88. Fahey J.W., Haristoy X., Dolan P.M., Kensler T.W., Scholtus I., Stephenson K.K., Talalay P., and Lozniewski A. Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 7610-7615
89. Wang Z.Y., Cheng S.J., Zhou Z.C., Athar M., Khan W.A., Bickers D.R., and Mukhtar H. Antimutagenic activity of green tea polyphenols. Mutat. Res. 223 (1989) 273-285
90. Correa P. The role of antioxidants in gastric carcinogenesis. Crit. Rev. Food Sci. Nutr. 53 (1995) 59-64
91. De Sanjose S., Munoz N., Sobala G., Vivas J., Peraza S., Cano E., Castro D., Sanchez V., Andrade O., Tompkins D., Schorah C.J., Axon A.T., Benz M., and Olivier W. Antioxidants, Helicobacter pylori' and stomach cancer in Venezuela. Eur. J. Cancer Prev. 5 (1996) 57-62
92. Khaled M.A., Sarker S.A., and Wahed M.A. Helicobacter pylori and vitamin A status in children. Am. J. Clin. Nutr. 66 (1997) 707
93. Domínguez Y.L., Hernández M., Matos C.M., and Zhou D. Is B vitamins deficiency associated with prevalence of Alzheimer's disease in uban elderly?. Nutr. Health 18 (2006) 103-118
94. Lewerin C., Jacobsson S., Lindstedt G., and Nilsson-Ehle H. Mol. Nutr. Food Res. 52 (2008) 386-387
95. Zafra-Stone S., Yasmin T., Bagchi M., Chatterjee A., Vinson J.A., and Bagchi D. Berry anthocyanins as novel antioxidants in human health and disease prevention. Mol. Food Res. 51 (2007) 675-683
96. Kusters J.G., Van Vliet A.H., and Kuipers E.J. Pathogenesis of Helicobacter pylori infection. Clin. Microbiol. Rev. 19 (2006) 449-490
97. Marshall B.J., and Windsor H.M. The relation of Helicobacter pylori to gastric adenocarcinoma and lymphoma: pathophysiology, epidemiology, screening, clinical presentation, treatment, and prevention. Med. Clin. North Am. 89 (2005) 313-344
98. J. Del Valle, W. Chey, J. Scheiman, Serum biomarkers for atrophic gastritis and antibodies against Helicobacter pylori in the elderly: implications for vitamin B12, folic acid and iron status and response to oral vitamin therapy, Acid Peptic Disorders, Lippincott Williams & Wilkins, Philadelphia, PA, Scand J Gastroenterol 43(9) (2008) 1050-1056.
99. Nomura A.M., Pérez-Pérez G.I., Lee J., Stemmermann G., and Blaser M.J. Relation between Helicobacter pylori cagA status and risk of peptic ulcer disease. Am. J. Epidemiol. 155 (2002) 1054-1059
100. Higashi H., Tsutsumi R., Muto S., Sugiyama T., Azuma T., Asaka M., and Hatakeyama M. SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein. Science 295 (2002) 683-686
101. McColl K.E., el-Omar E.M., and Gillen D. Alterations in gastric physiology in Helicobacter pylori infection: causes of different diseases or all epiphenomena?. Ital. J. Gastroenterol. Hepatol. 29 (1997) 459-464
102. Yamaoka Y., Kodama T., Gutierrez O., Kim J.G., Kashima K., and Graham D.Y. Relationship between Helicobacter pylori iceA, cagA, and vacA status and clinical outcome: studies in four different countries. J. Clin. Microbiol. 37 (1999) 2274-2279
103. Allen L.A., Schlesinger L.S., and Kang B. Virulent strains of Helicobacter pylori demonstrate delayed phagocytosis and stimulate homotypic phagosome fusion in macrophages. J. Exp. Med. 191 (2000) 115-128
104. Amieva M.R., and El-Omar E.M. Host-bacterial interactions in Helicobacter pylori infection. Gastroenterology 134 (2008) 306-323
105. Atherton J.C., Peek Jr. R.M., Tham K.T., Cover T.L., and Blaser M.J. Clinical and pathological importance of heterogeneity in vacA, the vacuolating cytotoxin gene of Helicobacter pylori. Gastroenterology 112 (1997) 92-99
106. Szabò I., Brutsche S., Tombola F., Moschioni M., Satin B., Telford J.L., Rappuoli R., Montecucco C., Papini E., and Zoratti M. Formation of anion-selective channels in the cell plasma membrane by the toxin VacA of Helicobacter pylori is required for its biological activity. EMBO J. 18 (1999) 5517-5527
107. Willhite D.C., and Blanke S.R. Helicobacter pylori vacuolating cytotoxin enters cells, localizes to the mitochondria, and induces mitochondrial membrane permeability changes correlated to toxin channel activity. Cell Microbiol. 6 (2004) 143-154
108. Willhite D.C., Cover T.L., and Blanke S.R. Cellular vacuolation and mitochondrial cytochrome c release are independent outcomes of Helicobacter pylori vacuolating cytotoxin activity that are each dependent on membrane channel formation. J. Biol. Chem. 278 (2003) 48204-48209
109. Atherton J.C., Cao P., Peek Jr. R.M., Tummuru M.K., Blaser M.J., and Cover T.L. Mosaicism in vacuolating cytotoxin alleles of Helicobacter pylori. Association of specific VacA types with cytotoxin production and peptic ulceration. J. Biol. Chem. 270 (1995) 17771-17777
110. Barer M.R., Elliott T.S., Berkeley D., Thomas J.E., and Eastham E.J. Cytopathic effects of Campylobacter pylori urease. J. Clin. Pathol. 41 (1988) 597
111. Bury-Moné S., Skouloubris S., Labigne A., and De Reuse H. The Helicobacter pylori UreI protein: role in adaptation to acidity and identification of residues essential for its activity and for acid activation. Mol. Microbiol. 42 (2001) 1021-1034
112. Gobert A.P., McGee D.J., Akhtar M., Mendz G.L., Newton J.C., Cheng Y., Mobley H.L., and Wilson K.T. Helicobacter pylori arginase inhibits nitric oxide production by eukaryotic cells: a strategy for bacterial survival. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 13844-13849
113. Evans D.J., and Evans D.G. Helicobacter pylori adhesins: review and perspectives. Helicobacter 5 (2000) 183-195
114. Ilver D., Arnqvist A., Ogren J., Frick I.M., Kersulyte D., Incecik E.T., Berg D.E., Covacci A., Engstrand L., and Borén T. Helicobacter pylori adhesion binding fucosylated histo-blood group antigens revealed by retagging. Science 279 (1998) 373-377
115. Guruge J.L., Falk P.G., Lorenz R.G., Dans M., Wirth H.P., Blaser M.J., Berg D.E., and Gordon J.I. Epithelial attachment alters the outcome of Helicobacter pylori infection. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 3925-3930
116. Appelmelk B.J., Simoons-Smit I., Negrini R., Moran A.P., Aspinall G.O., Forte J.G., De Vries T., Quan H., Verboom T., Maaskant J.J., Ghiara P., Kuipers E.J., Bloemena E., Tadema T.M., Townsend R.R., Tyagarajan K., Crothers Jr. J.M., Monteiro M.A., Savio A., and De Graaff J. Potential role of molecular mimicry between Helicobacter pylori lipopolysaccharide and host Lewis blood group antigens in autoimmunity. Infect. Immun. 64 (1996) 2031-2040
117. Ikehara Y., Nishihara S., Yasutomi H., Kitamura T., Matsuo K., Shimizu N., Inada K., Kodera Y., Yamamura Y., Narimatsu H., Hamajima N., and Tatematsu M. Polymorphisms of two fucosyltransferase genes (Lewis and Secretor genes) involving type I Lewis antigens are associated with the presence of anti-Helicobacter pylori IgG antibody. Cancer Epidemiol. Biomarkers Prev. 10 (2001) 971-977
118. Wu M.S., Chen C.J., Lin M.T., Wang H.P., Shun C.T., Sheu J.C., and Lin J.T. Genetic polymorphisms of cytochrome p450 2E1, glutathione S-transferase M1 and T1, and susceptibility to gastric carcinoma in Taiwan. Int. J. Colorectal Dis. 17 (2002) 338-343
119. Palli D., Saieva C., Gemma S., Masala G., Gomez-Miguel M.J., Luzzi I., D'Errico M., Matullo G., Ozzola G., Manetti R., Nesi G., Sera F., Zanna I., Dogliotti E., and Testai E. GSTT1 and GSTM1 gene polymorphisms and gastric cancer in a high-risk Italian population. Int. J. Cancer 115 (2005) 284-289
120. Izzotti A., De Flora S., Cartiglia C., Are B.M., Longobardi M., Camoirano A., Mura I., Dore M.P., Scanu A.M., Rocca P.C., Maida A., and Piana A. Interplay between Helicobacter pylori and host gene polymorphisms in inducing oxidative DNA damage in the gastric mucosa. Carcinogenesis 28 (2007) 892-898
121. Ibeanu G.C., Blaisdell J., Ferguson R.J., Ghanayem B.I., Brosen K., and Benhamou S. A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-Mephenytoin. J. Pharmacol. Exp. Ther. 290 (1999) 635-640
122. Sagar M., Tybring G., Dahl M.L., Bertilsson L., and Seensalu R. Effects of omeprazole on intragastic pH and plasma gastrin are dependent on the CYP2C19 polymorphism. Gastroenterology 119 (2000) 670-676
123. Take S., Mizuno M., Ishiki K., Nagahara Y., Yoshida T., and Inaba T. Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection. Am. J. Gastroenterol. 98 (2003) 2403-2408
124. Kawamura M., Ohara S., Koike T., Iijima K., Suzuki J., and Kayaba S. The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism. Aliment Pharmacol. Ther. 17 (2003) 965-973
125. Mizuki I., Shimoyama T., and Fukuda S. Association of gastric epithelial apoptosis with the ability of Helicobacter pylori to induce a neutrophil oxidative burst. J. Med. Microbiol. 49 (2000) 521-524
126. Murakami M., Asagoe K., Dekigai H., Kusaka S., Saita H., and Kita T. Products of neutrophil metabolism increase ammonia-induced gastric mucosal damage. Dig. Dis. Sci. 40 (1995) 268-273
127. Podrez E.A., Abu-Soud H.M., and Hazen S.L. Myeloperoxidase-generated oxidants and atherosclerosis. Free Radic. Biol. Med. 28 (2000) 1717-1725
128. Piedrafita F.J., Molander R.B., Vansant G., Orlova E.A., Pfahl M., and Reynolds W.F. An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element. J. Biol. Chem. 271 (1996) 14412-14420
129. Beales I.L., and Calam J. Interleukin 1 beta and tumour necrosis factor alpha inhibit acid secretion in cultured rabbit parietal cells by multiple pat Interleukin-1 and TNF-α inhibit gastric acid secretion 42. Gut 42 (1998) 227-234
130. Abraham S.C., Singh V.K., Yardley J.H., and Wu T.T. Hyperplastic polyps of the stomach: associations with histologic patterns of gastritis and gastric atrophy. Am. J. Surg. Pathol. 25 (2001) 1342-1344
131. El-Omar E.M., Carrington M., Chow W.H., McColl K.E., Bream J.H., Young H.A., Herrera J., Lissowska J., Yuan C.C., Rothman N., Lanyon G., Martin M., Fraumeni Jr. J.F., and Rabkin F.C.S. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 404 (2000) 398-402
132. Machado J.C., Figueiredo C., Canedo P., Pharoah P., Carvalho R., Nabais S., Castro Alves C., Campos M.L., Van Doorn L.J., Caldas C., Seruca R., Carneiro F., and Sobrinho-Simões M. A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology 125 (2003) 364-371
133. Amanda C., Augusto A., Fernanda Miguel A., Sérgio Mendonça B., José Pedrazzoli J.R., Sonia B., and Gurgueira A. Oxidative stress expression status associated to Helicobacter pylori virulence in gastric diseases. Clin. Biochem. 40 (2007) 615-622
134. Noach L.A., Basma N.B., Jansen J., Hoek F.J., van Deventer S.J., and Tytgat G.N. Mucosal tumor necrosis factor-a, interleukin-1b, and interleukin-8 production in patients with Helicobacter pylori infection. Scand. J. Gastroenterol. 29 (1994) 425-429
135. Hida N., Shimoyama Jr. T., Neville P., Dixon M.F., Axon A.T., and Shimoyama T. Increased expression of IL-10 and IL-12 (p40) mRNA in Helicobacter pylori infected gastric mucosa: relation to bacterial cag status and peptic ulceration. J. Clin. Pathol. 52 (1999) 658-664
136. Bauditz J., Ortner M., Bierbaum M., Niedobitek G., Lochs H., and Schreiber S. Production of IL-12 in gastritis relates to infection with Helicobacter pylori. Clin. Exp. Immunol. 117 (1999) 316-323
137. Suzuki T., Matsuo K., Ito H., Sawaki A., Hirose K., Hawaki K., Sato S., Nakamura T., Yamao K., Ueda R., and Tajima K. Smoking increases the treatment failure for Helicobacter pylori eradication. Am. J. Med. 119 (2006) 217-224
138. Izzotti A., Balansky R.M., Blagoeva P.M., Mircheva Z.I., Tulimiero L., Cartiglia C., and De Flora S. DNA alterations in rat organs following chronic exposure to cigarette smoke and/or ethanol ingestion. FASEB J. 12 (1998) 753-758
139. Hamajima N., Ito H., Matsuo K., Tajima K., and Tominaga S. Helicobacter pilori seropositivity, the interleukin 1B polymorphism, and smoking among firstvisit outpatients. Asian Pac. J. Cancer Prev. 3 (2002) 23-28
140. Hamajima N., Matsuo K., Suzuki T., Nakamura T., Matsuura A., Tajima K., and Tominaga S. Low expression myeloperoxidase negatively associated with Helicobacter pylori infection. Jpn. J. Cancer Res. 92 (2001) 488-493
141. Goto Y., Hamajima N., Honda H., Matsuo K., Yamamoto K., Tamakoshi A., Ando T., and Goto H. Association between Helicobacter pylori seropositivity and NAD(P)H quinone oxidoreductase 1 (NQO1) C609T polymorphism observed for outpatients and health checkup examinees. Gastric Cancer 8 (2005) 12-17
142. Lotito A.P., Muscara M.N., Kiss M.H., Teixeira S.A., Novaes G.S., Laurindo I.M., Silva C.A., and Mello S.B. Nitric oxide-derived species in synovial fluid from patients with juvenile idiopathic arthritis. J. Rheumatol. 31 (2004) 992-997
143. Schoneich S. Methionine oxidation by reactive oxygen species: reaction mechanisms and relevance to Alzheimer's disease. Biochim. Biophys. Acta 1703 (2005) 111-119
144. Mannick E.E., Bravo L.E., Zarama G., Realpe J.L., Zhang X.J., and Ruiz B. Inducible nitric oxide synthase, nytrotyrosinase, and apoptosis in Helicobacter pylori gastritis: effect of antibiotics and antioxidants. Cancer Res. 56 (1996) 3238-3243
145. Davies G.R., Simmonds N.J., Stevens T.R.J., Sheaff M.T., Banatvala N., Laurenso I.F., Blake D.R., and Rampton D.S. Helicobacter pylori stimulates antral mucosal reactive oxygen metabolite production in vivo. Gut 35 (1994) 179-185
146. Miedany Y., Baddour M., Ahmed I., and Fahmy H. Sjogren's syndrome: concomitant H. Pylori infection and possible correlation with clinical parameters. Joint Bone Spine 72 (2005) 135-141
147. Shirin H., Pinto J.T., Liu L.U., Merzianu M., Sordillo E.M., and Moss S.F. Helicobacter pylori decreases gastric mucosal glutathione. Cancer Lett. 164 (2001) 127-133
148. Naito Y., and Yoshikawa T. Molecular and cellular mechanisms involved in Helicobacter pylori-induced inflammation and oxidative stress. Free Radic. Biol. Med. 33 (2002) 323-336
149. Moshkowitz M., Brill S., Konikoff F.M., Averbuch M., Arber N., and Halpern Z. Additive deleterious effect of smoking on gastroduodenal pathology and clinical course in Helicobacter pylori-positive dyspeptic patients. Isr. Med. Assoc. J. 2 (2000) 892-895
150. Balansky R., Izzotti A., Scatolini L., D'Agostini F., and De Flora S. Induction by carcinogens and chemoprevention by N-acetylcysteine of adducts to mitochondrial DNA in rat organs. Cancer Res. 56 (1996) 1642-1647
151. Giovannucci E. Tomatoes, tomato-based products, lycopene, and cancer: review of the epidemiologic literature. J. Natl. Cancer Inst. 91 (1999) 317-331
152. Matsuo K., Hamajima N., Ikehara Y., Suzuki T., Nakamura T., Matsuura A., Tajima K., and Tominaga S. Smoking and polymorphisms of fucosyltransferase gene Le affect success of H. pylori eradication with lansoprazole, amoxicillin, and clarithromycin. Epidemiol. Infect. 130 (2003) 227-233